357 related articles for article (PubMed ID: 19640210)
1. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
Rabenda V; Hiligsmann M; Reginster JY
Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
[TBL] [Abstract][Full Text] [Related]
2. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence: impact on outcomes and health care resources.
Reginster JY
Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
[TBL] [Abstract][Full Text] [Related]
5. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
6. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
7. Overcoming problems with adherence to osteoporosis medication.
Rabenda V; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):677-89. PubMed ID: 21155701
[TBL] [Abstract][Full Text] [Related]
8. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
Cotté FE; Fautrel B; De Pouvourville G
Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
10. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
11. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
Beard MK
Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
Boonen S
Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
[TBL] [Abstract][Full Text] [Related]
14. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
16. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
Hiligsmann M; Boonen A; Rabenda V; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2012 Apr; 12(2):159-66. PubMed ID: 22458617
[TBL] [Abstract][Full Text] [Related]
17. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
Grazio S; Morović-Vergles J
Reumatizam; 2007; 54(2):89-92. PubMed ID: 18351154
[TBL] [Abstract][Full Text] [Related]
18. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Martens MG; Shaw H
South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
[TBL] [Abstract][Full Text] [Related]
19. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
[TBL] [Abstract][Full Text] [Related]
20. Approaches to osteoporosis: screening and implementing treatment in clinical practice.
Rawlins S
J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S39-44. PubMed ID: 19825318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
